Items tagged with Medicines
2022 WGND Annual Meeting (post)
The Stop TB Partnership Working Group on New Drugs (WGND)’ Annual Meeting will take place virtually on 3 November 2022.
GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with TB (post)
-- GSK3036656 demonstrated early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis
-- Treatment was generally well tolerated with no serious adverse events identified
-- Results demonstrate the potential for this asset to be a component of simpler TB treatment regimens in the future
-- TB remains leading global cause of death from infectious disease and new treatments are urgently needed
Calibr and Bill & Melinda Gates Medical Research Institute announce licensing agreement for novel candidate TB treatment compound (post)
LA JOLLA, Calif. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Calibr, a division of Scripps Research dedicated to the "bench to bedside" development of transformative medicines, and the Bill & Melinda Gates Medical Research Institute (Gates MRI), today announced a strategic licensing agreement to advance development of a novel investigational compound for tuberculosis treatment. Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment. Calibr will transition CLB073 to Gates MRI for further development.
RESIST-TB webinar: DR-TB drugs under the microscope (post)
RESIST-TB will host a webinar on 9 March 2023, Drug-resistant TB (DR-TB) drugs under the microscope. The speakers will present on pricing elements and intellectual property/licensing for DR-TB medicines.
Cornell-developed anti-TB compound headed to trials (post)
A novel compound that has the potential to starve the bacteria that causes tuberculosis – the world’s leading infectious killer after SARS-CoV2 – is entering human clinical trials.
Standigm and Institut Pasteur Korea identify lead compounds for resistant TB thanks to Right Foundation grant (post)
SEOUL, South Korea, April 4, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, and Korean non profit research institute Institut Pasteur Korea announced that they have jointly developed new lead compounds effective in treating resistant tuberculosis (TB). The two organizations conducted a technology acceleration grant project supported by the Right Foundation from 2021 to 2022. They achieved encouraging results by combining their core competencies of artificial intelligence (AI) platforms, infectious disease research capabilities and drug discovery technologies. This breakthrough demonstrates that AI technology can effectively address unmet medical needs for low and middle-income countries that tend to have higher than normal rates of resistant TB.
Novel drugs have potential for treating TB (post)
Tuberculosis, a bacterial lung infection, is one of the leading causes of death worldwide and is becoming increasingly resistant to antibacterial treatments.
WHO call for experts: Technical Advisory Group on dosing of TB medicines for adults and children (post)
The World Health Organization (WHO) is seeking experts to serve as members of the Technical Advisory Group on dosing of TB medicines for adults and children. For further details about the advisory group, the expert profiles being sought, the process for experts to express interest, and the process of selection, click here.
Finding a balance in antibiotic medicine: can we kill ‘bad’ bacteria while preserving the ‘good’? (post)
A study led by scientists at University of St Andrews has found that antibiotics used to treat tuberculosis kill other potentially useful bacteria.
Treating TB when antibiotics no longer work (post)
A research team has detected various substances that have a dual effect against tuberculosis: They make the bacteria causing the disease less pathogenic for human immune cells and boost the activity of conventional antibiotics.
Page 14 of 19 · Total posts: 0
←First 13 14 15 Last→